BioAtla, Inc.

How big is BioAtla, Inc.?

As of Jun 18, BioAtla, Inc. has a market capitalization of 22.78 million, with net sales of 11.00 million and a net profit of -61.87 million over the last four quarters. Shareholder's funds are 14.27 million, and total assets are 52.42 million as of Dec 24.

Market Cap: As of Jun 18, BioAtla, Inc. has a market capitalization of 22.78 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, BioAtla, Inc. reported net sales of 11.00 million and a net profit of -61.87 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 14.27 million, while total assets were reported at 52.42 million.

What does BioAtla, Inc. do?

BioAtla, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net loss of $15 million and a market cap of $22.78 million. It has no P/E ratio due to losses, a dividend yield of 0.00%, and a highly negative return on equity of -6,456.30%.

Overview:<BR>BioAtla, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -15 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 22.78 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -31.81 <BR>Return on Equity: -6,456.30% <BR>Price to Book: 22.78<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold BioAtla, Inc.?

Is BioAtla, Inc. technically bullish or bearish?

As of May 5, 2025, BioAtla, Inc. is in a mildly bearish trend, driven by daily moving averages and mixed monthly indicators, despite some mildly bullish signals from the weekly MACD and KST.

As of 5 May 2025, the technical trend for BioAtla, Inc. has changed from sideways to mildly bearish. The current stance is bearish, primarily driven by the daily moving averages indicating a bearish trend. Although the weekly MACD and KST are mildly bullish, the overall monthly indicators show mixed signals, with Bollinger Bands and KST suggesting bearishness. The RSI shows no signal, indicating a lack of momentum in either direction. Given the significant decline in stock performance over the past year and three years compared to the S&P 500, the bearish sentiment is reinforced.

Is BioAtla, Inc. overvalued or undervalued?

As of November 7, 2024, BioAtla, Inc. is rated as "risky" and overvalued due to high financial ratios and significant underperformance, with a Price to Book Value of 28.15 and a 72.74% decline in stock price over the past year.

As of 7 November 2024, BioAtla, Inc. has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued given its financial metrics and peer comparisons. Key ratios include a Price to Book Value of 28.15, an EV to EBIT of 0.05, and an EV to EBITDA of 0.06, which indicate significant valuation concerns, especially in light of its negative earnings.<BR><BR>In comparison to its peers, BioAtla's EV to EBITDA ratio of 0.1364 is notably better than CARA Therapeutics, Inc. at -8.0086, but still reflects a challenging financial position. Other peers, such as Compugen Ltd. with an EV to EBITDA of -3.4456, further highlight the risks associated with BioAtla's valuation. Additionally, the company's stock has underperformed significantly over the past year, with a decline of 72.74% compared to a 10.26% gain in the S&P 500, reinforcing the perception of overvaluation in the current market context.